PRP for Hair Loss: What Systematic Reviews Can and Cannot Show
Quick answer: Pooled reviews of small randomized trials report higher average hair density after platelet-rich plasma (PRP) than control under studied protocols. That is a signal, not a guarantee. Certainty and expected magnitude remain limited by low-quality evidence, high heterogeneity and publication bias; preparation and treatment methods differ, and recent pooled analyses did not find a clear improvement in hair diameter.
Editorial disclosure: This is a source-by-source summary of the cited research. It has not been independently reviewed by a clinician and is not individual medical advice. It does not diagnose hair loss, determine suitability, recommend a protocol or predict an outcome.
Meta-analysis of randomized trials; 2024 systematic review and meta-analysis.
The question these studies can answer
Most trials ask whether measured outcomes—such as hair count, density, diameter or the proportion of hairs in a growth phase—change after a defined PRP protocol, often compared with placebo on the other half of the scalp. They do not establish that every PRP preparation is equivalent or that an average measured change will be visibly important to every person.
Randomized evaluator-blinded half-head trial; randomized double-blind half-head trial.
What pooled reviews reported
A review published in a 2022 journal issue included 30 studies and 687 patients; its meta-analysis of 10 randomized trials reported increases in hair density and thickness. The same paper called for trials with lower risk of bias, more consistent protocols and better investigation of differences between studies.
Evans and colleagues, systematic review and meta-analysis.
A later meta-analysis included 10 trials with 555 treatment units. Its pooled estimate favored PRP for hair density, while the pooled difference in hair diameter was not statistically significant. The authors also reported larger density effects in trials with fewer than 30 participants, a pattern that makes the size and stability of the effect less certain.
Li and colleagues, meta-analysis of randomized trials.
A 2024 review of randomized trials reached a similarly cautious result: density favored PRP, but the studies were highly heterogeneous, the authors graded the evidence low quality and reported evident publication bias. Its pooled estimate for hair diameter crossed no difference.
Kieling and colleagues, 2024 systematic review and meta-analysis.
| Outcome | What the pooled evidence suggests | Important limit |
|---|---|---|
| Hair density | Average density favored PRP over control. | Protocols and sample sizes varied; an average result is not an individual prediction. |
| Hair diameter | Earlier pooled work reported improvement. | A later randomized-trial meta-analysis did not find a statistically significant pooled difference. |
| Durability | Some trials followed participants beyond the treatment course. | The evidence does not define one durable effect or one universal maintenance schedule. |
What two placebo-controlled trials add
One evaluator-blinded half-head trial enrolled 23 participants and analyzed 20 after three monthly treatments. It reported improvement in hair counts and density after PRP and explicitly said that larger controlled studies were needed. A separate double-blind half-head trial in 25 participants reported greater hair density on the PRP-treated side at six months.
Gentile and colleagues; Alves and Grimalt.
Why this matters: placebo-controlled within-person designs reduce some sources of variation, but samples of 20 and 25 people are too small to settle effectiveness across sexes, stages of loss, preparation methods and longer time horizons.
Why “most studies were positive” needs context
A 2020 systematic review found that 84% of 12 included trials reported a positive effect. However, only half demonstrated statistically significant improvement using objective measures; some other positive reports did not describe p values or statistical analysis. Counting positive studies therefore does not by itself establish the size, certainty or clinical importance of an effect.
Why one PRP result cannot represent every PRP protocol
The reviews report important variability between studies and do not establish one optimized preparation or treatment protocol. Because the interventions and measurements are not uniform, a pooled average should not be translated into a promise for a specific clinic protocol.
The need for protocol optimization and investigation of between-study variability is stated in the 2020 meta-analysis; trial-size and subgroup effects are reported in the later randomized-trial meta-analysis.
What the evidence does—and does not—say about harms
Review authors reported no serious adverse events in the included trials. That should not be read as proof that rare harms cannot occur: one review noted that only 2 of 7 studies reported adverse reactions, and small efficacy trials are not designed to exclude uncommon events. A published case letter described recurring transient lymphadenopathy after a combined microneedling and PRP intervention; one report cannot estimate frequency or show which component caused the event.
2022 systematic review safety summary; RCT review with adverse-event reporting context; indexed case letter.
A defensible conclusion
- Supported: PRP monotherapy has a positive average signal for hair density in androgenetic alopecia.
- Uncertain: the size of a visibly meaningful effect, the best preparation and schedule, durability beyond 12 months, and which subgroups are most likely to benefit.
- Not supported by these studies: guaranteed regrowth, a universal protocol, permanent results, or a personalized suitability decision without assessment.
Interpretation bounded to the systematic review, two recent randomized-trial meta-analyses, two placebo-controlled trials, and an additional systematic review.
Scope boundary and related reading
This page addresses PRP monotherapy evidence only. For how hair-loss patterns and history inform assessment, read Hair Loss: Patterns, Causes and Assessment. For a separate evidence comparison of PRP, GFC and mesotherapy, read PRP vs GFC vs mesotherapy. Neither page can select a treatment for an individual.
Primary source records
- Evans AG et al. Systematic review and meta-analysis. PMID 32410524.
- Li M et al. Meta-analysis of randomized controlled trials. PMID 37644190.
- Gentile P et al. Randomized placebo-controlled trial. PMID 26400925.
- Alves R, Grimalt R. Randomized double-blind placebo-controlled trial. PMID 27035501.
- Gentile P, Garcovich S. Systematic review. PMID 32295047.
- Recurring transient lymphadenopathy case letter. PMID 32278805.
- Kieling L et al. 2024 systematic review and meta-analysis of randomized trials. PMID 39013743.
- Zhang X et al. Systematic review and meta-analysis of randomized trials. PMID 37533146.
Evidence checked 5 August 2026. This page reports what the cited records support and keeps evidence, interpretation and uncertainty separate.